PBAC spurns tirzepatide for subsidy, again

5 minute read


Besides cost, the committee found the drug didn’t fulfill all the maker’s efficacy and safety claims.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×